HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

Market Cap	774.95B
Revenue (ttm)	54.93B
Net Income (ttm)	-22.79B
Shares Out	83.78M
EPS (ttm)	-275.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,188,470
Average Volume	1,108,331
Open	9,710.00
Previous Close	9,160.00
Day's Range	8,740.00 - 9,770.00
52-Week Range	4,780.95 - 16,857.00
Beta	-0.12
RSI	52.97
Earnings Date	Mar 25, 2025

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 93
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2024, HLB Therapeutics's revenue was 54.93 billion, an increase of 4.45% compared to the previous year's 52.59 billion. Losses were -22.79 billion, 890.1% more than in 2023.